MOTS-C
Mitochondrial Peptide for Metabolism, Energy, and Fat Loss Research
Overview
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a mitochondrial-derived peptide that plays a role in regulating metabolism and cellular energy balance. It is widely researched for its potential effects on fat metabolism, insulin sensitivity, and physical performance.
Key Benefits
Key research-backed areas of interest include:
Supports metabolic function and energy regulation
May help support healthy metabolic function and energy balance.
May improve insulin sensitivity
Studied for its potential to improve insulin sensitivity in research settings.
Promotes fat utilization and weight management
Investigated for its potential to support fat utilization and weight management.
Supports cellular energy production
May support mitochondrial function and cellular energy production.
May enhance physical performance and endurance
Explored for its potential to support physical performance and endurance.
Mechanism of Action
MOTS-C is believed to influence metabolic pathways by regulating glucose utilization and activating AMPK, a key enzyme involved in energy balance. It may help shift the body toward increased fat burning while improving overall metabolic efficiency.
Common Research Applications
Fat loss and weight management; Insulin resistance and metabolic health; Energy production and endurance studies; Age-related metabolic decline.
Dosing Protocol (Research Context)
In research settings, MOTS-C is commonly used in intermittent dosing protocols rather than daily continuous use. Typical protocols include 5 mg to 15 mg administered 2–3 times per week. Administration is typically performed via subcutaneous injection. Protocols may vary depending on the intended research focus, particularly in metabolic and performance-related studies.
Cycle Duration
Typical research cycles range from 4 to 6 weeks, often followed by a break period before repeating.
Reconstitution Guidelines
Common vial sizes include 10mg; Typically mixed with bacteriostatic water; Store refrigerated after reconstitution.
Half-Life
MOTS-C has a moderate half-life, allowing for less frequent dosing compared to daily peptides.
Stacking Options
Semaglutide – appetite and glucose control; Tirzepatide – metabolic and weight support; BPC-157 – recovery and tissue support.
Potential Side Effects
Generally well tolerated in research settings; Possible injection site irritation; Rare reports of fatigue or mild nausea.
This compound is not approved by the FDA for human use. It is intended for research purposes only.